国家集采药品接续采购开标，创新药ETF天弘（517380）标的指数收获六连阳，机构：看好业绩确定性强的龙头企业

Group 1 - The three major indices showed mixed performance, with the innovative drug sector demonstrating strong momentum, as evidenced by the Hang Seng Shanghai Shenzhen Hong Kong Innovative Drug Selected 50 Index rising by 2.26%, marking six consecutive days of gains [1] - Notable performers within the index included Xinlitai, which increased by nearly 7%, and both CSPC Pharmaceutical Group and Rongchang Biopharmaceutical (A) rising over 5%, while Innovent Biologics saw an increase of nearly 5% [1] - The Tianhong Innovative Drug ETF (517380) recorded a trading volume exceeding 37 million yuan, with a net inflow of 41.66 million yuan over three consecutive trading days, bringing its total circulation to 2.504 billion shares and a market size of 1.963 billion yuan [1] Group 2 - The Biopharmaceutical ETF (159859) closely tracks the Biopharmaceutical Index, which includes the top 30 stocks in the A-share market based on market capitalization and liquidity, reflecting the overall performance of the biopharmaceutical industry [2] - The recent national procurement round involved 316 commonly used drugs across 26 treatment areas, with participation from 5.1 million medical institutions and 1,091 domestic and foreign companies submitting 4,623 products for bidding, resulting in 4,163 products from 1,020 companies being shortlisted [2] - Haitong International Securities noted a recovery in market sentiment for the Hong Kong pharmaceutical sector after previous adjustments, highlighting strong performance expectations for internet healthcare and leading CXO/research service companies, while also recommending attention to quality innovative drug leaders that have seen significant price corrections [2]